Summary of clinical trials
| Study | RA population | Study location(s) | Time point analyses | Treatment arms (n) | ClinicalTrials.gov identifier | Primary publication |
|---|---|---|---|---|---|---|
| PRESERVE (N=826) | Moderate | Global: Asia, Australia, Europe, Latin America | Week 36 | ETN plus MTX (826)* | NCT00565409 | Smolen et al19 |
| COMET (N=528) | Early, moderate-to-severe | Global: Asia, Australia, Europe, North America, Scandinavia, South America, Middle East | Week 52 | ETN plus MTX (265)†; MTX (263) | NCT00195494 | Emery et al16 |
| TEMPO (N=459) | Established, moderate-to-severe | Global: Australia, Europe, Middle East, Scandinavia | Week 52 | ETN plus MTX (231)†; MTX (228) | NCT00393471 | Klareskog et al17 |
| APPEAL (N=300) | Established, moderate-to-severe | Asia-Pacific | Week 16 | ETN plus MTX (197)‡; DMARD+MTX (103) | NCT00422227 | Kim et al9 |
| LARA (N=421) | Established, moderate-to-severe | Latin America | Week 24 | ETN plus MTX (279)†; DMARD plus MTX (142) | NCT00848354 | Machado et al18 |
N (or n) represents the number of patients at final time point in this analysis.
*Open-label ETN 50 mg+MTX only.
†ETN 50 mg weekly plus MTX.
‡ETN 25 mg twice weekly (equivalent to ETN 50 mg weekly) plus MTX.
DMARD, disease-modifying antirheumatic drugs; ETN, etanercept; MTX, methotrexate; RA, rheumatoid arthritis.